IRCT20171104037212N2招募中3 期
Efficacy of hydrochlorothiazide at stone free time after extra corporeal shock wake lithotripsy on patients referred to ESWL ward of Moradi hospital of Rafsanjan
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 278
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- no limit 至 no limit（—）
- 性别
- All
入选标准
- •Patients with Renal pelvic stone
- •Stone size equal or below 20 millimeters
排除标准
- •Renal failure
- •History of ?Extar corporeal shock wave lithotripsy
- •History of renal surgery
- •History of stone passage
- •History of using Diuretic drugs
- •History of using smooth muscle relaxant drugs
- •Patients with moderate or severe hydronephrosis
研究者
相似试验
进行中（未招募）
不适用
Efficacy and Safety of Hydrochlorothiazide Used as Add-on Therapy in Moderately to Severely Hypertensive Patients not Adequately Controlled by Olmesartan Medoxomil 40 mg MonotherapyEssential hypertensionMedDRA version: 8.1Level: LLTClassification code 10015488Term: Essential hypertensionEUCTR2006-003876-37-CZDAIICHI SANKYO EUROPE GmbH2,220
进行中（未招募）
1 期
Efficacy and Safety of Hydrochlorothiazide Used as Add-on Therapy in Moderately to Severely Hypertensive Patients not Adequately Controlled by Olmesartan Medoxomil 40 mg MonotherapyEficacia y seguridad de Hidroclorotiazida, utilizada como terapia adicional, en pacientes con hipertensión moderada a severa no controlados adecuadamente con Olmesartan MEdoxomil 40 mg en monoterapiaEssential hypertensionHipertensión esencialMedDRA version: 8.1Level: LLTClassification code 10015488Term: Essential hypertensionEUCTR2006-003876-37-ESDAIICHI SANKYO EUROPE GmbH1,500
进行中（未招募）
不适用
Efficacy and Safety of Hydrochlorothiazide Used as Add-on Therapy in Moderately to Severely Hypertensive Patients not Adequately Controlled by Olmesartan Medoxomil 40 mg MonotherapyEssential hypertensionMedDRA version: 8.1Level: LLTClassification code 10015488Term: Essential hypertensionEUCTR2006-003876-37-DEDAIICHI SANKYO EUROPE GmbH1,500
进行中（未招募）
1 期
Efficacy and Safety of Hydrochlorothiazide Used as Add-on Therapy in Moderately to Severely Hypertensive Patients not Adequately Controlled by Olmesartan Medoxomil 40 mg MonotherapyEUCTR2006-003876-37-FRDAIICHI SANKYO EUROPE GmbH1,500
已完成
不适用
Bio equivalence study of Hydrochlorothiazide 50 mg tabletsIRCT20200513047423N4Fatak Chemie Pars24